STIMUFEND® (pegfilgrastim-fpgk) | Official Patient Website
Description: STIMUFEND® (pegfilgrastim-fpgk) is an FDA-approved biosimilar to Neulasta® indicated to decrease the incidence of infection in patients with non-myeloid cancer. View the full Prescribing Information and learn about clinical biosimilarity and supportive care.
Copay Savings Program
STIMUFEND has a newly established Q-Code: Q5127
The information provided on this site is intended for certified US healthcare professionals. By clicking the “Yes” button below, you confirm that you are a certified US healthcare professional.
STIMUFEND® (pegfilgrastim-fpgk) | Official Patient Website